{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:31:13Z","timestamp":1772803873077,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["study number 201749"],"award-info":[{"award-number":["study number 201749"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Short-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (SABA) bronchodilators help alleviate symptoms in chronic obstructive pulmonary disease (COPD) and may be a useful marker of symptom severity. This analysis investigated whether SABA use impacts treatment differences between maintenance dual- and mono-bronchodilators in patients with COPD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Early MAXimisation of bronchodilation for improving COPD stability (EMAX) trial randomised symptomatic patients with low exacerbation risk not receiving inhaled corticosteroids 1:1:1 to once-daily umeclidinium\/vilanterol 62.5\/25\u2009\u03bcg, once-daily umeclidinium 62.5\u2009\u03bcg or twice-daily salmeterol 50\u2009\u03bcg for 24\u2009weeks. Pre-specified subgroup analyses stratified patients by median baseline SABA use (low, &lt;\u20091.5 puffs\/day; high, \u22651.5 puffs\/day) to examine change from baseline in trough forced expiratory volume in 1\u2009s (FEV<jats:sub>1<\/jats:sub>), change in symptoms (Transition Dyspnoea Index [TDI], Evaluating Respiratory Symptoms-COPD [E-RS]), daily SABA use and exacerbation risk. A post hoc analysis used fractional polynomial modelling with continuous transformations of baseline SABA use covariates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, patients in the high SABA use subgroup (mean: 3.91 puffs\/day, <jats:italic>n<\/jats:italic>\u2009=\u20091212) had more severe airflow limitation, were more symptomatic and had worse health status versus patients in the low SABA use subgroup (0.39 puffs\/day, <jats:italic>n<\/jats:italic>\u2009=\u20091206). Patients treated with umeclidinium\/vilanterol versus umeclidinium demonstrated statistically significant improvements in trough FEV<jats:sub>1<\/jats:sub> at Week 24 in both SABA subgroups (59\u201374\u2009mL; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001); however, only low SABA users demonstrated significant improvements in TDI (high: 0.27 [<jats:italic>p<\/jats:italic>\u2009=\u20090.241]; low: 0.49 [<jats:italic>p<\/jats:italic>\u2009=\u20090.025]) and E-RS (high: 0.48 [<jats:italic>p<\/jats:italic>\u2009=\u20090.138]; low: 0.60 [<jats:italic>p<\/jats:italic>\u2009=\u20090.034]) scores. By contrast, significant reductions in mean SABA puffs\/day with umeclidinium\/vilanterol versus umeclidinium were observed only in high SABA users (high: \u2212\u20090.56 [<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001]; low: \u2212\u20090.10 [<jats:italic>p<\/jats:italic>\u2009=\u20090.132]). Similar findings were observed when comparing umeclidinium\/vilanterol and salmeterol. Fractional polynomial modelling showed baseline SABA use \u22654 puffs\/day resulted in smaller incremental symptom improvements with umeclidinium\/vilanterol versus umeclidinium compared with baseline SABA use &lt;\u20094 puffs\/day.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In high SABA users, there may be a smaller difference in treatment response between dual- and mono-bronchodilator therapy; the reasons for this require further investigation. SABA use may be a confounding factor in bronchodilator trials and in high SABA users; changes in SABA use may be considered a robust symptom outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Funding<\/jats:title>\n                <jats:p>GlaxoSmithKline (study number 201749 [NCT03034915]).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-020-01451-8","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:02:47Z","timestamp":1603360967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial"],"prefix":"10.1186","volume":"21","author":[{"given":"F.","family":"Maltais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. P.","family":"Naya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. F.","family":"Vogelmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. H.","family":"Boucot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bjermer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tombs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Compton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Kerwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12931-019-1027-9","volume":"20","author":"I Naya","year":"2019","unstructured":"Naya I, Lipson DA, Boucot I, Gakava L, Compton C. Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis. Respir Res. 2019;20:60.","journal-title":"Respir Res"},{"key":"1451_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","volume":"49","author":"JF Donohue","year":"2018","unstructured":"Donohue JF, Jones PW, Bartels C, Marvel J, D'Andrea P, Banerji D, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"1451_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4104\/pcrj.2010.00059","volume":"20","author":"MT Dransfield","year":"2011","unstructured":"Dransfield MT, Bailey W, Crater G, Emmett A, O'Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20(1):46\u201353.","journal-title":"Prim Care Respir J"},{"key":"1451_CR4","volume-title":"Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD)","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) 2012; https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease-copd."},{"issue":"1","key":"1451_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12890-015-0077-0","volume":"15","author":"CR Jenkins","year":"2015","unstructured":"Jenkins CR, Postma DS, Anzueto AR, Make BJ, Peterson S, Eriksson G, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulmon Med. 2015;15(1):97.","journal-title":"BMC Pulmon Med"},{"issue":"1","key":"1451_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/13696998.2016.1223085","volume":"20","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Naya I, Small M, Holbrook T, Wood R, Mullerova H, et al. Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study. J Med Econ. 2017;20(1):28\u201336.","journal-title":"J Med Econ"},{"issue":"1","key":"1451_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12931-017-0566-1","volume":"18","author":"YS Punekar","year":"2017","unstructured":"Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86.","journal-title":"Respir Res"},{"issue":"1","key":"1451_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, et al. Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.","journal-title":"Respir Res"},{"issue":"6","key":"1451_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23(6):932\u201346.","journal-title":"Eur Respir J"},{"issue":"3","key":"1451_CR10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1183\/09031936.02.00063702","volume":"19","author":"PW Jones","year":"2002","unstructured":"Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398\u2013404.","journal-title":"Eur Respir J"},{"key":"1451_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-014-0124-z","volume":"15","author":"NK Leidy","year":"2014","unstructured":"Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- respiratory symptoms tool (E-RS) in three clinical trials. Respir Res. 2014;15:124.","journal-title":"Respir Res"},{"issue":"3","key":"1451_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450\u2013504.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"1451_CR13","doi-asserted-by":"publisher","first-page":"818","DOI":"10.4187\/respcare.05905","volume":"63","author":"M George","year":"2018","unstructured":"George M. Adherence in asthma and COPD: new strategies for an old problem. Respir Care. 2018;63(6):818\u201331.","journal-title":"Respir Care"},{"issue":"9","key":"1451_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","volume":"7","author":"S Pascoe","year":"2019","unstructured":"Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745\u201356.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1451_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","volume":"6","author":"M Bafadhel","year":"2018","unstructured":"Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117\u201326.","journal-title":"Lancet Respir Med"},{"key":"1451_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2147\/COPD.S119908","volume":"12","author":"JF Donohue","year":"2017","unstructured":"Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, et al. Comparative efficacy of long-acting \u03b22-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulm Dis. 2017;12:367\u201381.","journal-title":"Int J Chron Obstruct Pulm Dis"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-020-01451-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01451-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T23:10:21Z","timestamp":1634857821000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01451-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01451-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EMAX was conducted according to the principles of the Declaration of Helsinki and each site was required to obtain ethics committee\/institutional review board approval. Written informed consent was obtained from each patient prior to study screening.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IHB, PWJ, CC and DAL are employees of GlaxoSmithKline (GSK) and hold stocks and shares in GSK. IPN was an employee of GSK at the time of the study, holds stocks and shares in GSK and is a contingent worker on assignment at AstraZeneca. LT is a contingent worker on assignment at GSK. FM has received research grants for participating in multicentre trials for AstraZeneca, Boehringer Ingelheim, GSK, Sanofi and Novartis, and has received unrestricted research grants and personal fees from Boehringer Ingelheim, Grifols and Novartis. CFV has received grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Mundipharma, Novartis and the German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), and has received personal fees from AstraZeneca, Boehringer Ingelheim, Berlin Chemie\/Menarini, Chiesi, CSL Behring, GSK, Grifols, MedUpdate, Mundipharma, Novartis, Nuvaira and Teva. LB has received honoraria for giving a lecture or attending an advisory board for Airsonett, ALK-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Meda, Novartis and Teva. EMK has served on advisory boards, speaker panels or received travel reimbursement from Amphastar, AstraZeneca, Boehringer Ingelheim, GSK, Mylan, Novartis, Pearl, Sunovion, Teva and Theravance, and has received consulting fees from Cipla and GSK. ELLIPTA and DISKUS are owned by\/licensed to the GSK group of companies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}